Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
LONDON, May 23, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Jefferies Healthcare Conference
Date: June 8, 2017
Time: 11:30 AM EDT
Location: New York, NY
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||||
| Aubrey Powell / James White | ||||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||||
| ICR, Inc. (US Media and Investor enquiries) | ||||||
| James Heins | Tel: +1 203-682-8251 [email protected] | |||||
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |
